ETON PHARMACEUTICALS INC (ETON)

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Acquisition bolsters Eton’s commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving...

Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial

Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE®

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical...

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

Amglidia® has been approved by the European Medicines Agency (EMA) and is commercially available in EuropeStrong strategic fit with Eton’s existing...

Friday Sector Laggards: Biotechnology, Drugs

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Reported total revenue of $10.3 million and GAAP Net Income of $0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire...

Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the

SWK Holdings Provides Portfolio Update

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions Acquisition to...

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical...

ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024

ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eton Pharmaceuticals (NASDAQ:ETON) just reported results for the second quarter...

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growthNew...

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the

SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July ...

ETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

ETON stock results show that Eton Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

ETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eton Pharmaceuticals (NASDAQ:ETON) just reported results for the first quarter ...

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

•  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth•  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400•  Management to hold conference call today at 4:30pm ET

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing...

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak...